Key statistics
On Monday, BridgeBio Pharma Inc (BBIO:NSQ) closed at 27.19, 25.76% above the 52 week low of 21.62 set on Jun 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.81 |
---|---|
High | 30.51 |
Low | 26.86 |
Bid | 27.40 |
Offer | 27.50 |
Previous close | 23.42 |
Average volume | 3.45m |
---|---|
Shares outstanding | 188.99m |
Free float | 153.53m |
P/E (TTM) | -- |
Market cap | 4.43bn USD |
EPS (TTM) | -2.41 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
- Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
- BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
- BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
- BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
- BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024
- BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
- BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
- BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
More ▼